NEW HAVEN, Connecticut, August 29, 2026, 18:04 (EDT)
- BioXcel shares closed at $0.1814, down 74.76%, on 58.56 million shares.
- Teva offered $57.5 million upfront for substantially all operating assets.
- The bid includes up to $67.5 million of contingent development payments.
- Chapter 11 financing adds $19 million of new money and a $58.25 million roll-up.
BioXcel Therapeutics, Inc. (NASDAQ: BTAI) lost nearly three-quarters of its value Friday after entering Chapter 11. The $0.1814 close left its market capitalization near $5.50 million.
The selloff exposes a sharp distinction between asset value and equity value. Teva’s $57.5 million upfront offer equals roughly 10.5 times BioXcel’s market capitalization, yet those proceeds sit inside a bankruptcy waterfall.
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) is the stalking-horse bidder. It would acquire IGALMI and worldwide rights tied to the drug’s pending at-home indication Teva announcement.
The proposed consideration is $57.5 million in cash plus assumed liabilities. Another $67.5 million depends on development milestones, taking nominal potential consideration to $125 million.
| Value layer | Amount | Multiple of BTAI market cap |
|---|---|---|
| BTAI market capitalization | $5.50 million | 1.0x |
| Teva upfront bid | $57.5 million | 10.5x |
| Contingent payments | Up to $67.5 million | 12.3x |
| Maximum nominal consideration | $125 million | 22.7x |
| DIP new money | $19 million | 3.5x |
| DIP roll-up loans | Up to $58.25 million | 10.6x |
The court-supervised sale remains open to higher offers. BioXcel said IGALMI will remain commercially available while the process continues company statement.
Chief Executive Vimal Mehta said the process provides “a clear framework to pursue a value-maximizing transaction.” The filing followed a review of strategic alternatives.
The financing structure helps explain the stock’s reaction. BioXcel can draw $19 million of new debtor-in-possession financing in two $9.5 million tranches.
Existing secured obligations can also become as much as $58.25 million of roll-up loans. Those claims rank ahead of common equity in the reorganization process SEC filing.
Operating figures show why outside capital became necessary. First-quarter cash and restricted cash totaled $17.2 million, while the net loss reached $12.7 million.
IGALMI revenue was only $206,000 during the quarter. Cost of goods sold was $283,000, while operating expenses totaled $10.2 million first-quarter results.
The next product catalyst is the November 14, 2026, FDA action date. The pending application seeks at-home use for acute agitation associated with bipolar disorders or schizophrenia.
Risks are unusually high. A rival bidder may not emerge, the court may change sale terms, milestone payments may never arrive, and creditor claims could consume the proceeds before shareholders receive anything.
The 74.76% decline therefore looks less like a verdict on IGALMI’s science. It reflects the market’s estimate of residual value after financing, liabilities, court costs and execution risk Reuters.
